Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Drug class
3.2. Market Snippet by Distribution Channel
3.3. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.2. Drivers
4.2.1. Rising prevalence of heart diseases
4.2.2. Increasing drugs and alcohol abuse
4.3. Restraints:
4.3.1. Side-effects of dilated cardiomyopathy drugs
4.4. Opportunity
4.5. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Epidemiology
5.3. Pipeline analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
6. By Drug class
6.1. Introduction
6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment.
6.3. Market Attractiveness Index, By Drug Class Segment
6.3.1. Angiotensin-converting enzyme (ACE) Inhibitors*
6.3.1.1. Introduction
6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
6.3.2. Beta-blockers
6.3.3. Aldosterone antagonists
6.3.4. Angiotensin II Receptor Blockers
6.3.5. Others
7. By Distribution Channel
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
7.3. Market Attractiveness Index, By Distribution Channel Segment
7.3.1. Hospitals & Clinics*
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.2. Online Channels
7.3.3. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. The U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. The U.K.
8.3.5.3. France
8.3.5.4. Italy
8.3.5.5. Spain
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. Australia
8.5.5.5. Rest of Asia Pacific
8.6. The Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. AstraZeneca plc*
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Key Highlights
10.1.4. Financial Overview
10.2. Zensun Shanghai Sci & Tech Co Ltd
10.3. Pfizer Inc.
10.4. Capricor Therapeutics, Inc.
10.5. MyoKardia
10.6. Kasiak Research Pvt. Ltd.
10.7. Array BioPharma
10.8. Vericel Corporation
10.9. t2cure GmbH (*List is not exhaustive)
11. DataM Intelligence
11.1. Appendix
11.2. About Us and Services
11.3. Contact Us